Phase 3 Readout
VRDN: Phase 3 Topline: A Randomized, Double-masked, Controlled, Safety and Tolerability Study of VRDN-003 in Participants W
October 1, 2026 · vrdn-003. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 1, 2026
- Company
- Viridian Therapeutics, Inc.\DE (VRDN)
- Drug
- vrdn-003
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Randomized, Double-masked, Controlled, Safety and Tolerability Study of VRDN-003 in Participants W
- Drug
- vrdn-003
- Indication
- Thyroid Eye Disease (TED)